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Sergio Giralt, Edward Stadtmauer, Phillip McCarthyMultiple myeloma (MM) is a neoplastic disorder
characterized by malignant plasma cell proliferation,
bone destruction, and immunodeficiency [1]. Conven-
tional treatmentswithchemotherapy and radiation ther-
apy are noncurative but improve quality of life and
duration of survival [2]. High-dose therapy followed
by autografting or allografting can result in long-term
disease control in a fraction of patients, but relapse and
death from disease progression remain the most impor-
tant causes of treatment failure [3].Maintenance therapy
post stem cell transplantation (SCT) has been proposed
as a strategy to improve treatment outcomes [4].
Maintenance therapy with interferon has been at-
tempted, and did not result in significant improvement
in progression free (PFS) or overall survival (OS) [4,5].
Recently, 3 randomized trials have shown that the use
of the immune modulatory agent thalidomide when
given postautologous transplant resulted in superior
event-free survival (EFS) compared to transplant fol-
lowed by placebo [6-8]. Notwithstanding, because of
neurotoxic effects, most patients are unable to take
thalidomide for more than 12 months, and many
patients who received this agent as induction therapy
refuse to take it as maintenance because of poor
tolerability [4,8].
Newer immunomodulatory drugs (IMiDs) such as
lenalidomide have recently demonstrated high response
rates and favorable side effect profiles in upfront and sal-
vage trials. Two phase III trials of lenalidomide and
dexamethasone versus dexamethasone alone for
relapsed/refractory MM reported response rates of
61% with combination therapy compared to 22%
with dexamethasone alone [9,10].Department of Blood and Marrow Transplantation, Uni-
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6/j.bbmt.2010.11.016During 2010, 2 large randomized trials were pre-
sented at the meetings of the American Society of
Clinical Oncology in Chicago and the the American
Society of Hematology in Orlando exploring the use
of single-agent lenalidomide as posttransplant mainte-
nance therapies [11,12].
McCarthy et al. [11] presented the results of
CALGB 100104, whose primary endpoint was to inves-
tigate if maintenance lenalidomide would prolong time
to progression (TTP) following single autologous stem
cell transplantation (auto-SCT). Patients with chemo-
sensitive disease after an initial auto-SCTwere random-
ized at day 100-110 post autoSCT to lenalidomide 10
mg/day or placebo until disease progression. The study
was unblinded in 12/09 because of the superiority of the
study arm. Of 460 randomized patients, 33% of the
required number of events (progression or death before
progression) have been observed. The median follow-
up is 17.5 months. The number of events among 231
patients randomized to lenalidomide was 44 compared
to 91 among 229 patients randomized to placebo. The
1-sided unadjusted P-value was \.0001 and the esti-
mated hazard ratio (HR) was 0.39 (95% confidence
interval [CI] 5 0.24, 0.53), corresponding to a 61%
reduction in event risk (progression or death) in the
lenalidomide arm. The estimated median TTP was
22.5 months for the placebo arm and the estimated
median TTP is 42.3 months for the study arm. Benefits
were seen regardless of whether patients received lena-
lidomide or thalidomide during their pretransplant
induction therapy. When comparing pooled Gr 3-5
AEs for lenalidomide versus placebo postrandomiza-
tion, there were significantly more episodes of throm-
bocytopenia (11% versus 3%, P 5 .01), neutropenia
(44% versus 8%, P \.0001) and anemia (5% versus
1%, P 5 .0082) with lenalidomide. No significant
differences in the fatigue, neuropathy, rash, or thom-
boembolism were observed. Lenalidomide patients dis-
continued therapy because of AEsmore frequently than
placebo (13% versus 1%) [11].
At ASCO2010, Attal presented the results of a sim-
ilar trial (IFM 05-02) performed by the Intergroup
Francophone du Myelome, which enrolled 614 pa-
tients who had undergone ASCT for nonprogressvie
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received a 2-month consolidation with full-dose lena-
lidomide followed by a randomization of 307 patients
to placebo and 307 patients to 10 mg to 15 mg daily
lenalidomide until relapse/progression. After a median
follow-up of 24 months, only 25% of the lenalidomide
group experienced progression or death compared
with 47% of the placebo group. Maintenance with
lenalidomide improved 3-year PFS from randomiza-
tion to 68% in the lenalidomide group in comparison
to 34% in the placebo group (HR 5 0.46). Benefits
were seen regardless of the response to induction and
transplant therapy [12].
These 2 studies now leave us with the following
conclusions: (1) lenalidomide maintenance can effec-
tively delay disease progression postauto-SCT for mye-
loma, but it is unclear whether there will be an impact
on survival. (2) It is uncertain whether all patients
should receive lenalidomide as maintenance therapy
or whether a strategy of early intervention upon first
sign of progression may be equally effective in low-
risk patients. (3) Post-SCT lenalidomide is well toler-
ated but long-term follow-up is still needed and optimal
duration of therapy posttransplant is unknown.
For now, one practical approach would dictate that
lenalidomide maintenance should be considered stan-
dard for patients not achieving a complete remission
(CR) after SCT, and for high-risk patients even if
they achieve a CR. For patients with low-risk disease
who have achieved a CR after SCT the risk/benefits
of lenalidomide maintenance versus watchful waiting
should be discussed until we have more data regarding
survival benefits.
A recent study by the italian myeloma group exam-
ined melphalan, prednisone, and lenalidomide (MPR)
versus Tandem Transplant with Melphalan (200 mg/
m2) and found no difference in outcome between the
2 groups at a median follow-up of 14.1 months. The
Mel 200 and MPR arms had a PFS for both arms
was 91% at 12 months and a OS of 97 and 98%, re-
spectively [13]. A longer follow-up will be necessary
to determine if there is a PFS or OS benefit to either
arm. Of note, even in a nontransplant study comparing
MPR versus MP in older, nontransplant candidates,
MPR (median PFS not reached) was found to reduce
the risk of progression by 58% when compared to
MP (median PFS 13 months (P 5 .0001). However,
there was no difference in OS at a median followup
of 21 months. Thus, even in a nontransplant study,
the addition of lenalidomide to MP has not yet been
shown to improve OS. Another important study that
has just opened is a French-American study that will
examine the role of lenalidomide, bortezomib, and
dexamethasone (RVD) versus high-dose melphalan
and autotransplant. This study, along with the Italian
Multiple Myeloma Network Italian Multiple Mye-
loma Network (GIMEMA), may answer importantquestions as to which patients will benefit from auto-
transplant versus continued chemotherapy.
Allogeneic SCT (alloSCT) represents a cellular
form of maintenance therapy. Allograft recipients have
lifetime donor-derived immunity that can mediate
a graft-versus-myeloma effect. The role of allogeneic
transplantation as frontline therapy for myeloma has
been controversial.A series of biologic allocation studies
comparing tandem auto/allo-SCT with double auto-
SCT inMMhave been performed and recently summa-
rized [14]. In the French study, patients with an
HLA-identical sibling donor and high-riskMMdefined
by beta-2 microglobulin and deletion of chromosome
13 by fluorescent in situ hybridization (FISH) were
candidates for ASCT followed by reduced-intensity
conditioning (RIC) allo-SCT, although patients with-
out a sibling donor were treated with melphalan 220
mg/m2 and a second autologous transplant. Utilizing
an intent-to-treat analysis, with a median follow-up of
56 months, no difference in EFS was observed. Never-
theless, there was a trend for a superiorOS in the double
ASCT trial (median 48 versus 34months,P5 .07). This
studywas critiqued for the inclusionofhigh-doseantith-
ymocyte globulin (ATG) 12.5 mg/kg in the condition-
ing regimen and the use of low-dose busulfan as
conditioning regimen [15].
The Spanish PETHEMA found a trend for better
PFS (P 5 .08), but did not observe a difference in
EFS and OS between 85 patients receiving tandem
ASCT compared with 25 patients treated with auto-/
allo-SCT, although higher CR rates after the allo-
SCT, were achieved (40% versus 11%; P\ .001).42
Complicating the interpretation of this study is the
low number of patients in each arm [16].
Bruno et al. [17] reported on 82 patients with an
HLA-identical sibling donor assigned to be treated
with auto/allo-SCT (conditioning: low-dose TBI and
fludarabine only) who achieved higher CR and signif-
icantly longer PFS andOS compared to the 80 patients
assigned to the tandem auto-SCT arm. After the
second transplant, CR rates were 55% versus 26%
(P\.004), median PFS durations were 36 versus 29
months (P \.02), and OS durations were 80 versus
54 months (P \.01), respectively. The TRM was
only 11%. This study has been criticized because of
the poor results seen in the control group and the
lack of an appropriate control.
In the HOVON 54 study, patients with an HLA-
identical sibling donor included in the HOVON 50
study (phase III study for the evaluation of thalidomide
combined with HDM) could proceed to RIC allo-SCT
between 2 and 6 months after auto-SCT, whereas the
otherpatientswere assigned to thalidomideor interferon
maintenance after the first auto-SCT. No differences
in PFS and OS were found during an interim analysis
that included 126 patients with a donor and 141 patients
without a donor [18]. In the EBMT study, PFS at
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18% for tandem auto-SCT and OS 65% and 57%, re-
spectively. This trend for improvement was seen in pa-
tients with both deletion 13 and nondeletion 13 [19].
The German Multiple Myeloma Study Group
(DSMMM) performed a prospective study comparing
double auto-SCT (HDM200) with auto/allo-SCT
(fludarabine/melphalan). Allocation to either treatment
arm was based on the availability of an HLA-matched
(onemismatch allowed) sibling ormatchedunrelated do-
nor (MUD). Preliminary analysis showed a higher CR
rate in allograft recipients when compared to autografts.
However, theprojectedOSat3 yearswas70%fordouble
auto-SCT versus 60% for the auto/allo-SCT patients.
TRM at 2 years from allo-SCT was 12.7% [20].
A more definite conclusion about the role of allo-
SCT in MM may come from 3 other prospective
donor versus no donor studies with larger groups of pa-
tients that were performed in the United States, the
DutchHOVON, and the EBMT. The large U.S. mul-
ticenter trial from the Blood and Marrow Transplant
Clinical Trials Network (BMT CTN) comparing tan-
dem auto-SCTwith auto/allo-SCT completed the tar-
geted accrual in March 2007 with more than 150
patients biologically allocated to the auto/allo-SCT
group. The results from this study will be released in
the meeting of the American Society of Hematology
in December of 2010, and will be discussed by Dr. Ed-
ward Stadtmauer in the TandemMeetings in Orlando.
In summary, with the conclusion of the BMT-CTN
trial more than 5 large trials have been performed ex-
ploring the potential benefits of allografting as consoli-
dation of an initial response in myeloma patients.
Although some studies demonstrated benefit for allog-
rafting in regard to disease response and progression
free survival, only 1 study was shown to have a survival
benefit. Thus, until a clear cut benefit for allogeneic
SCT is seen it should continue to be performed in the
context of a clinical trial. Many such trials are currently
ongoing, particularly in thehigh-riskor relapsed setting.ACKNOWLEDGMENTS
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